Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
NCT07868939 on ClinicalTrials.gov · last registry update 2026-10-16
Registered but not yet open, with 560 participants planned. Due to report October 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily. Sponsors move these dates routinely; any movement since this site started watching is listed below. VK2735 is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- VK2735
- Sponsor
- Viking Therapeutics, Inc.
- Sponsor type
- Industry
- Enrollment
- 560
- Started
- 2026-11
- Primary completion
- 2028-10 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-10-09 | First seen in registry | Registered as NOT_YET_RECRUITING, P3 |
Primary outcome
Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily
Conditions studied
Weight Loss
Every field above is taken directly from the registry record. See all detected changes across the class, or the VK2735 page for this molecule’s full trial and approval history.